Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Drammen – page 42

616 clinical trials in Drammen, Norway across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Drammen at a glance
616
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

616 trials in Drammen

Open in trial search

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Pfizer Inc.

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiovascular disorder+1

Not recruiting

Study on Long-Term Effects of Lerodalcibep for Lowering Cholesterol in Patients with Familial Hypercholesterolemia or Cardiovascular Disease Risks

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lerodalcibep
  • Sponsor:LIB Therapeutics Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on Zanubrutinib for Patients with Primary Cold Agglutinin Disease

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab
  • Sponsor:Celgene International II S.a.r.l.

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Drammen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on various cancer types, including pancreatic ductal cancer, small-cell lung cancer, and advanced melanoma. Studies evaluate new combination therapies and treatment approaches.

  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Colon Cancer Treatment

Research emphasizes improving survival rates and treatment efficacy through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into cardiovascular diseases and preventive treatments. Trials explore new approaches for stroke prevention and management of heart conditions.

  • Atrial Fibrillation Management
  • Stroke Prevention
  • Atherosclerotic Disease

Focus on developing innovative antiplatelet therapies and investigating cardiovascular safety in various patient populations.

03 Chronic Disease Management

Studies addressing chronic conditions including Multiple Sclerosis, Crohn's Disease, and Rheumatoid Arthritis. Trials evaluate new therapeutic approaches and drug combinations.

  • COPD Treatment
  • Inflammatory Conditions
  • Metabolic Disorders

Research aims to improve disease control and patient outcomes through innovative treatment strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.